Vanguard Fiduciary Trust
AVIR icon

Vanguard Fiduciary Trust’s Atea Pharmaceuticals AVIR Stock Holding History

Vanguard Fiduciary Trust’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.18M Sell
469,801
-14,904
-3% -$74.1K ﹤0.01% 2621
2026
Q1 		$2.61M Buy
+484,705
New +$2.23M ﹤0.01% 2435

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Fiduciary Trust's AVIR Position: Q2 2026 in Review

Vanguard Fiduciary Trust reduced its Atea Pharmaceuticals (AVIR) stake by 3.1% in Q2 2026, selling an estimated $74.1K and leaving 469,801 shares worth $2.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2621.

Vanguard Fiduciary Trust first reported a position in AVIR in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.61M in Q1 2026. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Vanguard Fiduciary Trust held 469,801 shares of Atea Pharmaceuticals worth $2.18M as of Q2 2026.
  • Vanguard Fiduciary Trust sold 14,904 Atea Pharmaceuticals shares in Q2 2026, an estimated $74.1K.
  • Atea Pharmaceuticals made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2621 holding.
  • Vanguard Fiduciary Trust first reported a position in Atea Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Atea Pharmaceuticals position peaked at $2.61M in Q1 2026.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.